Prestige Biologics Co Ltd (334970)

KOSDAQ

Currency in KRW

3,630

-130(-3.46%)

Closed·01/08

Fair Value

Unlock Value

Day's Range

3,600

3,755

52 wk Range

3,235

7,830

334970 Financial Summary

A brief financial summary of Prestige Biologics Co Ltd as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-7.77

Price/Book2.13

Debt / Equity68%

Return on Equity-34.26%

Dividend Yield0.00%

EBITDA-22.20B

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

30/06

2024

30/06

Income Statement

Total Revenues

aa.aa

3,226.84

15.57

1,730.26

2,169.04

Gross Profit

aa.aa

2,346.75

-8.71

499.3

-8,843.71

Operating Income

aa.aa

-26,836.89

-36,631.25

-22,105.26

-33,429.99

Net Income

aa.aa

-39,377.96

-49,717.9

-17,979.64

-29,373.79

Balance Sheet

Total Assets

aa.aa

206,768.01

258,079.24

305,753.04

289,414.06

Total Current Liabilities

aa.aa

28,392.56

32,551.65

89,097.64

92,305.79

Total Equity

aa.aa

106,831.95

117,611.35

99,802.78

71,682.12

Cash Flow

Levered Free Cash Flow

aa.aa

-127,116.7

-98,249.94

-27,811.5

Cash from Operations

aa.aa

-25,749.73

-34,124.2

-4,449.04

-8,345.46

Cash from Investing

aa.aa

-97,910.05

-83,665.45

-34,480.72

-7,926.57

Cash from Financing

aa.aa

156,312.12

96,462.86

53,979.4

344.5

Net Change in Cash

aa.aa

32,533.44

-21,392.48

30,052.01

-15,927.53

* In Millions of KRW (except for per share items)

Earnings

Latest Release

May 15, 2025

EPS / Forecast

-96.00 / --

Revenue / Forecast

3.48B / --

EPS Revisions

Unlock

Last 90 days

FAQ

What were Prestige Biologics Co's earnings for the latest quarter?

The Prestige Biologics Co EPS (TTM) is -472.27. Prestige Biologics Co reported sales of 3,480.87, net income of -7,459.62, and EPS of -96.00 for the latest quarter.

What was Prestige Biologics Co's net income for the latest quarter?

Prestige Biologics Co's net income for the latest quarter was -7,459.62.

How did Prestige Biologics Co's performance compare year-over-year in the latest quarter?

The company's revenue moved from 3,022.96 in the previous quarter to 3,480.87 in the latest quarter, and net income moved from -13,928.83 to -7,459.62 compared to the previous quarter.

What is Prestige Biologics Co's net profit margin on a TTM basis?

Prestige Biologics Co's trailing twelve months (TTM) net profit margin is -1,354.23%.

How does Prestige Biologics Co's debt to equity ratio compare to industry standards?

Prestige Biologics Co's total debt-to-equity ratio is 68.00%.

What is Prestige Biologics Co's return on investment on a TTM basis?

Prestige Biologics Co's trailing twelve months (TTM) return on investment (ROI) is -34.26%.

Did Prestige Biologics Co gain or lose cash last quarter?

In the latest quarter, Prestige Biologics Co's net change in cash was -5,938.88 million.

What were Prestige Biologics Co's total assets and liabilities in the latest quarter?

As of the latest quarter, Prestige Biologics Co reported total assets of 277,729.97 million and total liabilities of 108,689.81 million.

How has Prestige Biologics Co's total revenue grown this year?

Prestige Biologics Co's total revenue was 3,022.96 in the previous quarter and 3,480.87 in the latest quarter.

What is Prestige Biologics Co's gross margin on a TTM basis?

Prestige Biologics Co's trailing twelve months (TTM) gross margin is -264.00%.

What was Prestige Biologics Co's revenue per share for the latest quarter?

Prestige Biologics Co's revenue per share for the latest quarter was 14,131.22.

NSE 30

5,185.55

+49.87

+0.97%

NSE All Share

141,263.05

+1,399.53

+1.00%

US 30

43,577.00

-554.0

-1.26%

US 500

6,235.60

-103.9

-1.64%

FTSE 100

9,068.58

-64.23

-0.70%

DAX

23,425.97

-639.50

-2.66%

South Africa Top 40

90,140.55

-640.82

-0.71%

Market Movers

Name	Last	Chg. %	Vol.
Fcmb	10.800	+8.00%	277.21M
Fidelitybk	21.200	+0.71%	85.55M
Zenith Bank	76.50	0.00%	38.61M
UBA	49.25	-0.71%	28.79M
Guaranty Trust Holding	99.50	-1.00%	26.28M
Lafarge Africa	149.00	0.00%	9.23M
Aradel Holdings	520.00	-1.89%	6.28M

Name	Last	Chg. %	Vol.
UAC Of Nigeria	88.30	+9.96%	3.53M
BUA Cement	148.00	+9.63%	2.84M
Veritas Kapital	1.39	+9.45%	41.54M
Betaglas	408.50	+9.22%	839.96K
Wema Bank	23.90	+8.64%	19.51M
Prestige	1.26	+8.62%	7.19M
Custodian Allied	39.00	+8.33%	752.29K

Name	Last	Chg. %	Vol.
Dangote Sugar	66.15	-10.00%	4.68M
Champion Brew	12.51	-10.00%	6.95M
Oando Plc	53.10	-10.00%	10.38M
Cornerst	4.15	-9.78%	2.49M
Abbey Mortgage Bank	5.27	-9.76%	460.62K
International Energy Insurance	2.13	-9.75%	1.22M
University Pre	5.100	-9.73%	908.00K

Trending Stocks

Name	Last	Chg. %	Vol.
MTN Nigeria	480.00	+1.69%	1.49M
UBA	49.25	-0.71%	28.79M
Betaglas	408.50	+9.22%	839.96K
Honeywell Flour Mills Plc	24.000	-2.04%	7.86M
Julius Berger	126.00	0.00%	119.12K

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaa Aaaaaaaaaa A	528.30	+38.66%	732.54
A Aaa Aaaa	67.00	+24.27%	83.26

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Prestige Biologics Co Ltd (334970)

334970 Financial Summary

Key Ratios

Statements Highlights

Earnings

FAQ

What were Prestige Biologics Co's earnings for the latest quarter?

What was Prestige Biologics Co's net income for the latest quarter?

How did Prestige Biologics Co's performance compare year-over-year in the latest quarter?

What is Prestige Biologics Co's net profit margin on a TTM basis?

How does Prestige Biologics Co's debt to equity ratio compare to industry standards?

What is Prestige Biologics Co's return on investment on a TTM basis?

Did Prestige Biologics Co gain or lose cash last quarter?

What were Prestige Biologics Co's total assets and liabilities in the latest quarter?

How has Prestige Biologics Co's total revenue grown this year?

What is Prestige Biologics Co's gross margin on a TTM basis?

What was Prestige Biologics Co's revenue per share for the latest quarter?

Trending Stocks